• Order to parcel locker

    Order to parcel locker
  • easy pay

    easy pay
  • Reduced price
Therapeutic Targeting of RAS Mutant Cancers

Therapeutic Targeting of RAS Mutant Cancers

9781009073646
107.10 zł
96.39 zł Save 10.71 zł
Lowest price within 30 days before promotion: 96.39 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations. This has led to the first FDA approval for a RAS targeted therapy. This new agent is a covalent inhibitor that reacts with the cysteine residue created by a codon 12 glycine to cysteine (G12C) mutation within KRAS. Mutant-specific strategies may also exist for other KRAS single nucleotide variants, and recent studies provide examples and mechanisms.
Product Details
97901
9781009073646
9781009073646

Data sheet

Publication date
2022
Issue number
1
Cover
paperback
Pages count
75
Dimensions (mm)
152.00 x 228.00
Weight (g)
80
  • Introduction; RAS Biology; Oncogenic RAS; RAS Targeting; Downstream Targeting; Upstream Targeting; Targeting Specific RAS Mutants; KRAS G12C Targeting; Direct Targeting of Other RAS Proteins; KRAS G12R Pancreatic Cancer; KRAS G13D Colorectal Cancer; Summary; References.
Comments (0)